Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alison Johnson is active.

Publication


Featured researches published by Alison Johnson.


Journal of the National Cancer Institute | 2009

A Case–Control Study of Smoking and Bladder Cancer Risk: Emergent Patterns Over Time

Dalsu Baris; Margaret R. Karagas; Castine Verrill; Alison Johnson; Angeline S. Andrew; Carmen J. Marsit; Molly Schwenn; Joanne S. Colt; Sai Cherala; Claudine Samanic; Richard Waddell; Kenneth P. Cantor; Alan R. Schned; Nathaniel Rothman; Jay H. Lubin; Joseph F. Fraumeni; Robert N. Hoover; Karl T. Kelsey; Debra T. Silverman

BACKGROUNDnCigarette smoking is a well-established risk factor for bladder cancer. The effects of smoking duration, intensity (cigarettes per day), and total exposure (pack-years); smoking cessation; exposure to environmental tobacco smoke; and changes in the composition of tobacco and cigarette design over time on risk of bladder cancer are unclear.nnnMETHODSnWe examined bladder cancer risk in relation to smoking practices based on interview data from a large, population-based case-control study conducted in Maine, New Hampshire, and Vermont from 2001 to 2004 (N = 1170 urothelial carcinoma case patients and 1413 control subjects). We calculated odds ratios (ORs) and 95% confidence intervals (CIs) using unconditional logistic regression. To examine changes in smoking-induced bladder cancer risk over time, we compared odds ratios from New Hampshire residents in this study (305 case patients and 335 control subjects) with those from two case-control studies conducted in New Hampshire in 1994-1998 and in 1998-2001 (843 case patients and 1183 control subjects).nnnRESULTSnRegular and current cigarette smokers had higher risks of bladder cancer than never-smokers (for regular smokers, OR = 3.0, 95% CI = 2.4 to 3.6; for current smokers, OR = 5.2, 95% CI = 4.0 to 6.6). In New Hampshire, there was a statistically significant increasing trend in smoking-related bladder cancer risk over three consecutive periods (1994-1998, 1998-2001, and 2002-2004) among former smokers (OR = 1.4, 95% CI = 1.0 to 2.0; OR = 2.0, 95% CI = 1.4 to 2.9; and OR = 2.6, 95% CI = 1.7 to 4.0, respectively) and current smokers (OR = 2.9, 95% CI = 2.0 to 4.2; OR = 4.2, 95% CI = 2.8 to 6.3; OR = 5.5, 95% CI = 3.5 to 8.9, respectively) (P for homogeneity of trends over time periods = .04). We also observed that within categories of intensity, odds ratios increased approximately linearly with increasing pack-years smoked, but the slope of the increasing trend declined with increasing intensity.nnnCONCLUSIONSnSmoking-related risks of bladder cancer appear to have increased in New Hampshire since the mid-1990s. Based on our modeling of pack-years and intensity, smoking fewer cigarettes over a long time appears more harmful than smoking more cigarettes over a shorter time, for equal total pack-years of cigarettes smoked.


Human Molecular Genetics | 2011

A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3

Montserrat Garcia-Closas; Yuanqing Ye; Nathaniel Rothman; Jonine D. Figueroa; Núria Malats; Colin P. Dinney; Nilanjan Chatterjee; Ludmila Prokunina-Olsson; Zhaoming Wang; Jie Lin; Francisco X. Real; Kevin B. Jacobs; Dalsu Baris; Michael J. Thun; Immaculata De Vivo; Demetrius Albanes; Mark P. Purdue; Manolis Kogevinas; Ashish M. Kamat; Seth P. Lerner; H. Barton Grossman; Jian Gu; Xia Pu; Amy Hutchinson; Yi Ping Fu; Laurie Burdett; Meredith Yeager; Wei Tang; Adonina Tardón; Consol Serra

Genome-wide and candidate-gene association studies of bladder cancer have identified 10 susceptibility loci thus far. We conducted a meta-analysis of two previously published genome-wide scans (4501 cases and 6076 controls of European background) and followed up the most significant association signals [17 single nucleotide polymorphisms (SNPs) in 10 genomic regions] in 1382 cases and 2201 controls from four studies. A combined analysis adjusted for study center, age, sex, and smoking status identified a novel susceptibility locus that mapped to a region of 18q12.3, marked by rs7238033 (P = 8.7 × 10(-9); allelic odds ratio 1.20 with 95% CI: 1.13-1.28) and two highly correlated SNPs, rs10775480/rs10853535 (r(2)= 1.00; P = 8.9 × 10(-9); allelic odds ratio 1.16 with 95% CI: 1.10-1.22). The signal localizes to the solute carrier family 14 member 1 gene, SLC14A1, a urea transporter that regulates cellular osmotic pressure. In the kidney, SLC14A1 regulates urine volume and concentration whereas in erythrocytes it determines the Kidd blood groups. Our findings suggest that genetic variation in SLC14A1 could provide new etiological insights into bladder carcinogenesis.


Pharmacogenetics and Genomics | 2010

A single nucleotide polymorphism tags variation in the arylamine N-acetyltransferase 2 phenotype in populations of European background

Montserrat Garcia-Closas; David W. Hein; Debra T. Silverman; Núria Malats; Meredith Yeager; Kevin B. Jacobs; Mark A. Doll; Jonine D. Figueroa; Dalsu Baris; Molly Schwenn; Manolis Kogevinas; Alison Johnson; Nilanjan Chatterjee; Lee E. Moore; Timothy Moeller; Francisco X. Real; Stephen J. Chanock; Nathaniel Rothman

The arylamine N-acetyltransferase 2 (NAT2) slow acetylation phenotype is an established risk factor for urinary bladder cancer. We reported earlier on this risk association using NAT2 phenotypic categories inferred from NAT2 haplotypes based on seven single nucleotide polymorphisms (SNPs) in a study in Spain. In a subsequent genome-wide scan, we have identified a single common tag SNP (rs1495741) located in the 3′ end of NAT2 that is also associated with bladder cancer risk. The aim of this report is to evaluate the agreement between the common tag SNP and the 7-SNP NAT2 inferred phenotype. The agreement between the 7-SNP NAT2 inferred phenotype and the tag SNP, rs1495741, was initially assessed in 2174 individuals from the Spanish Bladder Cancer Study (SBCS), and confirmed in a subset of individuals from the Main and Vermont component the New England Bladder Cancer Study (NEBCS). We also investigated the association of rs1495741 genotypes with NAT2 catalytic activity in cryopreserved hepatocytes from 154 individuals of European background. We observed very strong agreement between rs1495741 and the 7-SNP inferred NAT2 phenotype: sensitivity and specificity for the NAT2 slow phenotype was 99 and 95%, respectively. Our findings were replicated in an independent population from the NEBCS. Estimates for the association between NAT2 slow phenotype and bladder cancer risk in the SBCS and its interaction with cigarette smoking were comparable for the 7-SNP inferred NAT2 phenotype and rs1495741. In addition, rs1495741 genotypes were strongly related to NAT2 activity measured in hepatocytes (P<0.0001). A novel NAT2 tag SNP (rs1495741) predicts with high accuracy the 7-SNP inferred NAT2 phenotype, and thus can be used as a sole marker in pharmacogenetic or epidemiological studies of populations of European background. These findings illustrate the utility of tag SNPs, often used in genome-wide association studies (GWAS), to identify novel phenotypic markers. Further studies are required to determine the functional implications of rs1495741 and the structure and evolution of the haplotype on which it resides.


Proceedings of the National Academy of Sciences of the United States of America | 2012

Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk

Yi Ping Fu; Indu Kohaar; Nathaniel Rothman; Julie Earl; Jonine D. Figueroa; Yuanqing Ye; Núria Malats; Wei Tang; Luyang Liu; Montserrat Garcia-Closas; Brian Muchmore; Nilanjan Chatterjee; Mc Anthony Tarway; Manolis Kogevinas; Patricia Porter-Gill; Dalsu Baris; Adam Mumy; Demetrius Albanes; Mark P. Purdue; Amy Hutchinson; Alfredo Carrato; Adonina Tardón; Consol Serra; Reina García-Closas; Josep Lloreta; Alison Johnson; Molly Schwenn; Margaret R. Karagas; Alan R. Schned; W. Ryan Diver

Genome-wide association studies have identified a SNP, rs2294008, on 8q24.3 within the prostate stem cell antigen (PSCA) gene, as a risk factor for bladder cancer. To fine-map this region, we imputed 642 SNPs within 100 Kb of rs2294008 in addition to 33 markers genotyped in one of the reported genome-wide association study in 8,652 subjects. A multivariable logistic regression model adjusted for rs2294008 revealed a unique signal, rs2978974 (r2 = 0.02, D′ = 0.19 with rs2294008). In the combined analysis of 5,393 cases and 7,324 controls, we detected a per-allele odds ratio (OR) = 1.11 [95% confidence interval (CI) = 1.06–1.17, P = 5.8 × 10−5] for rs2294008 and OR = 1.07 (95% CI = 1.02–1.13, P = 9.7 × 10−3) for rs2978974. The effect was stronger in carriers of both risk variants (OR = 1.24, 95% CI = 1.08–1.41, P = 1.8 × 10−3) and there was a significant multiplicative interaction (P = 0.035) between these two SNPs, which requires replication in future studies. The T risk allele of rs2294008 was associated with increased PSCA mRNA expression in two sets of bladder tumor samples (n = 36, P = 0.0007 and n = 34, P = 0.0054) and in normal bladder samples (n = 35, P = 0.0155), but rs2978974 was not associated with PSCA expression. SNP rs2978974 is located 10 Kb upstream of rs2294008, within an alternative untranslated first exon of PSCA. The non-risk allele G of rs2978974 showed strong interaction with nuclear proteins from five cell lines tested, implying a regulatory function. In conclusion, a joint effect of two PSCA SNPs, rs2294008 and rs2978974, suggests that both variants may be important for bladder cancer susceptibility, possibly through different mechanisms that influence the control of mRNA expression and interaction with regulatory factors.


Occupational and Environmental Medicine | 2011

Occupation and bladder cancer in a population-based case–control study in Northern New England

Joanne S. Colt; Margaret R. Karagas; Molly Schwenn; Dalsu Baris; Alison Johnson; Patricia A. Stewart; Castine Verrill; Lee E. Moore; Jay H. Lubin; Mary H. Ward; Claudine Samanic; Nathaniel Rothman; Kenneth P. Cantor; Laura E. Beane Freeman; Alan R. Schned; Sai Cherala; Debra T. Silverman

Objectives We used data from a large, population-based case–control study in Maine, New Hampshire, and Vermont to examine relationships between occupation, industry and bladder cancer risk. Methods Lifetime occupational histories were obtained by personal interview from 1158 patients newly diagnosed with urothelial carcinoma of the bladder in 2001–2004, and from 1402 population controls. Unconditional logistic regression was used to calculate ORs and 95% CIs, adjusted for demographic factors, smoking and employment in other high-risk occupations. Results Male precision metalworkers and metalworking/plasticworking machine operators had significantly elevated risks and significant trends in risk with duration of employment (precision metalworkers: OR 2.2, 95% CI 1.4 to 3.4, ptrend=0.0065; metalworking/plasticworking machine operators: OR 1.6, 95% CI 1.01 to 2.6, ptrend=0.047). Other occupations/industries for which risk increased significantly with duration of employment included: for men, textile machine operators, mechanics/repairers, automobile mechanics, plumbers, computer systems analysts, information clerks, and landscape industry workers; for women, service occupations, health services, cleaning and building services, management-related occupations, electronic components manufacturing and transportation equipment manufacturing. Men reporting use of metalworking fluids (MWF) had a significantly elevated bladder cancer risk (OR 1.7, 95% CI 1.1 to 2.5). Conclusions Our findings support the hypothesis that some component(s) of MWF may be carcinogenic to the bladder. Our results also corroborate many other previously reported associations between bladder cancer risk and various occupations. More detailed analyses using information from the studys job-specific questionnaires may help to identify MWF components that may be carcinogenic, and other bladder carcinogens associated with a variety of occupations.


International Journal of Cancer | 2011

Hair dye use and risk of bladder cancer in the New England bladder cancer study.

Stella Koutros; Debra T. Silverman; Dalsu Baris; Shelia Hoar Zahm; Lindsay M. Morton; Joanne S. Colt; David W. Hein; Lee E. Moore; Alison Johnson; Molly Schwenn; Sai Cherala; Alan R. Schned; Mark A. Doll; Nathaniel Rothman; Margaret R. Karagas

Aromatic amine components in hair dyes and polymorphisms in genes that encode enzymes responsible for hair dye metabolism may be related to bladder cancer risk. We evaluated the association between hair dye use and bladder cancer risk and effect modification by N‐acetyltransferase‐1 (NAT1), NAT2, glutathione S‐transferase Mu‐1 (GSTM1) and glutathione S‐transferase theta‐1 (GSTT1) genotypes in a population‐based case–control study of 1193 incident cases and 1418 controls from Maine, Vermont and New Hampshire enrolled between 2001 and 2004. Individuals were interviewed in person using a computer‐assisted personal interview to assess hair dye use and information on potential confounders and effect modifiers. No overall association between age at first use, year of first use, type of product, color, duration or number of applications of hair dyes and bladder cancer among women or men was apparent, but increased risks were observed in certain subgroups. Women who used permanent dyes and had a college degree, a marker of socioeconomic status, had an increased risk of bladder cancer [odds ratio (OR) = 3.3, 95% confidence interval (CI): 1.2–8.9]. Among these women, we found an increased risk of bladder cancer among exclusive users of permanent hair dyes who had NAT2 slow acetylation phenotype (OR = 7.3, 95% CI: 1.6–32.6) compared to never users of dye with NAT2 rapid/intermediate acetylation phenotype. Although we found no relation between hair dye use and bladder cancer risk in women overall, we detected evidence of associations and gene‐environment interaction with permanent hair dye use; however, this was limited to educated women. These results need confirmation with larger numbers, requiring pooling data from multiple studies.


Cancer Epidemiology, Biomarkers & Prevention | 2012

Correlation of LINE-1 Methylation Levels in Patient-Matched Buffy Coat, Serum, Buccal Cell, and Bladder Tumor Tissue DNA Samples

Dana M. van Bemmel; Petra Lenz; Linda M. Liao; Dalsu Baris; Lawrence R. Sternberg; Andrew C. Warner; Alison Johnson; Michael Jones; Masatoshi Kida; Molly Schwenn; Alan R. Schned; Debra T. Silverman; Nathaniel Rothman; Lee E. Moore

Background: Evidence suggests that global methylation levels in blood cell DNA may be a biomarker for cancer risk. To date, most studies have used genomic DNA isolated from blood or urine as a surrogate marker of global DNA methylation levels in bladder tumor tissue. Methods: A subset of 50 bladder cancer cases was selected from the New England Bladder Cancer Case–Control Study. Genomic DNA was isolated from buffy coat, buccal cells, serum, and formalin-fixed, paraffin-embedded tissue for each participant. DNA methylation at four CpG sites within the long interspersed nucleotide element (LINE-1) repetitive element was quantified using pyrosequencing and expressed as a mean methylation level across sites. Results: Overall, the mean percent (%) LINE-1 5-methylcytosine (%5MeC) level was highest in serum (80.47% ± 1.44%) and lowest in bladder tumor DNA (61.36% ± 12.74%) and levels varied significantly across tissue types (P = 0.001). An inverse association between LINE-1 mean %5MeC and tumor stage (P = 0.001) and grade (P = 0.002) was observed. A moderate correlation between patient-matched serum and buffy coat DNA LINE-1 %5MeC levels was found (r = 0.32, P = 0.03) but levels were uncorrelated among other matched genomic DNA samples. Conclusions: The mean promoter LINE-1 %5MeC measurements were correlated between buffy coat and serum DNA samples. No correlation was observed between genomic DNA sources and tumor tissues; however a significant inverse association between tumor percent LINE-1 methylation and tumor stage/grade was found. Impact: LINE-1 methylation measured in case blood DNA did not reflect that observed in bladder tumor tissue but may represent other factors associated with carcinogenesis. Cancer Epidemiol Biomarkers Prev; 21(7); 1143–8. ©2012 AACR.


Occupational and Environmental Medicine | 2012

Comparison of two expert-based assessments of diesel exhaust exposure in a case–control study: programmable decision rules versus expert review of individual jobs

Anjoeka Pronk; Patricia A. Stewart; Joseph Coble; Hormuzd A. Katki; David C. Wheeler; Joanne S. Colt; Dalsu Baris; Molly Schwenn; Margaret R. Karagas; Alison Johnson; Richard Waddell; Castine Verrill; Sai Cherala; Debra T. Silverman; Melissa C. Friesen

Objectives Professional judgment is necessary to assess occupational exposure in population-based case–control studies; however, the assessments lack transparency and are time-consuming to perform. To improve transparency and efficiency, we systematically applied decision rules to questionnaire responses to assess diesel exhaust exposure in the population-based case–control New England Bladder Cancer Study. Methods 2631 participants reported 14u2005983 jobs; 2749 jobs were administered questionnaires (‘modules’) with diesel-relevant questions. We applied decision rules to assign exposure metrics based either on the occupational history (OH) responses (OH estimates) or on the module responses (module estimates); we then combined the separate OH and module estimates (OH/module estimates). Each job was also reviewed individually to assign exposure (one-by-one review estimates). We evaluated the agreement between the OH, OH/module and one-by-one review estimates. Results The proportion of exposed jobs was 20–25% for all jobs, depending on approach, and 54–60% for jobs with diesel-relevant modules. The OH/module and one-by-one review estimates had moderately high agreement for all jobs (κw=0.68–0.81) and for jobs with diesel-relevant modules (κw=0.62–0.78) for the probability, intensity and frequency metrics. For exposed subjects, the Spearman correlation statistic was 0.72 between the cumulative OH/module and one-by-one review estimates. Conclusions The agreement seen here may represent an upper level of agreement because the algorithm and one-by-one review estimates were not fully independent. This study shows that applying decision-based rules can reproduce a one-by-one review, increase transparency and efficiency, and provide a mechanism to replicate exposure decisions in other studies.


Journal of the National Cancer Institute | 2015

Modification of Occupational Exposures on Bladder Cancer Risk by Common Genetic Polymorphisms

Jonine D. Figueroa; Stella Koutros; Joanne S. Colt; Manolis Kogevinas; Montserrat Garcia-Closas; Francisco X. Real; Melissa C. Friesen; Dalsu Baris; Patricia A. Stewart; Molly Schwenn; Alison Johnson; Margaret R. Karagas; Karla R. Armenti; Lee E. Moore; Alan R. Schned; Petra Lenz; Ludmila Prokunina-Olsson; A. Rouf Banday; Ashley Paquin; Kris Ylaya; Joon-Yong Chung; Stephen M. Hewitt; Michael L. Nickerson; Adonina Tardón; Consol Serra; Alfredo Carrato; Reina García-Closas; Josep Lloreta; Núria Malats; Joseph F. Fraumeni

Few studies have demonstrated gene/environment interactions in cancer research. Using data on high-risk occupations for 2258 case patients and 2410 control patients from two bladder cancer studies, we observed that three of 16 known or candidate bladder cancer susceptibility variants displayed statistically significant and consistent evidence of additive interactions; specifically, the GSTM1 deletion polymorphism (P interaction ≤ .001), rs11892031 (UGT1A, P interaction = .01), and rs798766 (TMEM129-TACC3-FGFR3, P interaction = .03). There was limited evidence for multiplicative interactions. When we examined detailed data on a prevalent occupational exposure associated with increased bladder cancer risk, straight metalworking fluids, we also observed statistically significant additive interaction for rs798766 (TMEM129-TACC3-FGFR3, P interaction = .02), with the interaction more apparent in patients with tumors positive for FGFR3 expression. All statistical tests were two-sided. The interaction we observed for rs798766 (TMEM129-TACC3-FGFR3) with specific exposure to straight metalworking fluids illustrates the value of integrating germline genetic variation, environmental exposures, and tumor marker data to provide insight into the mechanisms of bladder carcinogenesis.


Cancer Epidemiology, Biomarkers & Prevention | 2012

Cell Cycle Control in Urothelial Carcinoma: Large-scale Tissue Array Analysis of Tumor Tissue from Maine and Vermont

Lenz P; Pfeiffer R; Dalsu Baris; Alan R. Schned; Mikiko Takikita; Poscablo Mc; Molly Schwenn; Alison Johnson; Michael Jones; Masatoshi Kida; Kenneth P. Cantor; N. Rothman; Debra T. Silverman; Stephen M. Hewitt; Lee E. Moore

Background: Cell-cycle proteins are important predictive markers in urothelial carcinoma but may also exhibit exposure-specific heterogeneity. Methods: Tumor tissue from 491 bladder cancer cases enrolled in the Maine and Vermont component of the New England Bladder Cancer Study was assembled as tissue microarrays and examined for aberrant expression of p53, p63, p16, cyclin D1, Rb, and Ki-67. The association between expression and histopathology, demographics, and cigarette smoking was examined using χ2 tests, multivariable Poisson, and multinomial regression models. Results: We found that overexpression of p53 and Ki-67 was associated with high-stage/grade tumors [relative risk (RR), 1.26; Ptrend = 0.003; and RR, 3.21; Ptrend < 0.0001, respectively], whereas expression of p63 and p16 was decreased in high-stage/grade tumors (RR, 0.52; Ptrend < 0.0001; and RR, 0.88; Ptrend = 0.04, respectively). No significant aberrations of cell-cycle proteins were identified using various smoking variables and multiple statistical models. Conclusion: The results of this population-based study of histologically confirmed urothelial carcinomas show significant aberration of cell-cycle proteins p53, p63, p16, and Ki-67, but not Rb or cyclin D1. p53 showed the most significant heterogeneity with respect to tumor stage and grade, especially when stratified for different staining intensities using novel digital image analysis techniques. Our findings do not support that smoking modifies expression of cell-cycle proteins. Impact: Our study shows significant heterogeneity in the expression of key cell-cycle proteins that are associated with disease progression in bladder cancer. Further studies may lead to the identification of biomarkers and their multiplexed interactions as useful prognostic and therapeutic targets. Cancer Epidemiol Biomarkers Prev; 21(9); 1555–64. ©2012 AACR.

Collaboration


Dive into the Alison Johnson's collaboration.

Top Co-Authors

Avatar

Dalsu Baris

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Molly Schwenn

Centers for Disease Control and Prevention

View shared research outputs
Top Co-Authors

Avatar

Debra T. Silverman

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Lee E. Moore

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Nathaniel Rothman

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Joanne S. Colt

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Sai Cherala

New Hampshire Department of Health

View shared research outputs
Top Co-Authors

Avatar

Kenneth P. Cantor

United States Department of Health and Human Services

View shared research outputs
Researchain Logo
Decentralizing Knowledge